{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:15:45Z","timestamp":1791346545023,"version":"4.3.1"},"reference-count":205,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"am","delay-in-days":189,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","award":["R01HL169761"],"award-info":[{"award-number":["R01HL169761"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012394","name":"Robert J Kleberg Jr and Helen C Kleberg Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012394","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomaterials"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.biomaterials.2025.123314","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T02:52:09Z","timestamp":1743735129000},"page":"123314","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Engineering adeno-associated viral vectors for CRISPR\/Cas based in vivo therapeutic genome editing"],"prefix":"10.1016","volume":"321","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3582-2074","authenticated-orcid":false,"given":"Buhle","family":"Moyo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas B.C.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7080-8238","authenticated-orcid":false,"given":"Ishika I.","family":"Khondaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5501-554X","authenticated-orcid":false,"given":"Gang","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.biomaterials.2025.123314_bib1","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1038\/nprot.2013.143","article-title":"Genome engineering using the CRISPR-Cas9 system","volume":"8","author":"Ran","year":"2013","journal-title":"Nat. Protoc."},{"issue":"6096","key":"10.1016\/j.biomaterials.2025.123314_bib2","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1126\/science.1225829","article-title":"A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity","volume":"337","author":"Jinek","year":"2012","journal-title":"Science"},{"issue":"6121","key":"10.1016\/j.biomaterials.2025.123314_bib3","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1126\/science.1231143","article-title":"Multiplex genome engineering using CRISPR\/Cas systems","volume":"339","author":"Cong","year":"2013","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.biomaterials.2025.123314_bib4","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nm.3793","article-title":"Therapeutic genome editing: prospects and challenges","volume":"21","author":"Cox","year":"2015","journal-title":"Nat Med"},{"issue":"6405","key":"10.1016\/j.biomaterials.2025.123314_bib5","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1126\/science.aat5011","article-title":"CRISPR-Cas guides the future of genetic engineering","volume":"361","author":"Knott","year":"2018","journal-title":"Science"},{"issue":"7794","key":"10.1016\/j.biomaterials.2025.123314_bib6","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41586-020-1978-5","article-title":"The promise and challenge of therapeutic genome editing","volume":"578","author":"Doudna","year":"2020","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.biomaterials.2025.123314_bib7","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s41576-022-00541-1","article-title":"Prime editing for precise and highly versatile genome manipulation","volume":"24","author":"Chen","year":"2023","journal-title":"Nat. Rev. Genet."},{"issue":"7","key":"10.1016\/j.biomaterials.2025.123314_bib8","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/s41551-021-00760-7","article-title":"CRISPR-based diagnostics","volume":"5","author":"Kaminski","year":"2021","journal-title":"Nat. Biomed. Eng."},{"issue":"15","key":"10.1016\/j.biomaterials.2025.123314_bib9","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1016\/j.cell.2022.03.045","article-title":"Therapeutic in vivo delivery of gene editing agents","volume":"185","author":"Raguram","year":"2022","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.biomaterials.2025.123314_bib10","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1055\/s-0040-1721451","article-title":"World-first Phase I clinical trial for CRISPR-cas9 PD-1-Edited T-cells in advanced nonsmall cell lung cancer","volume":"7","author":"Liu","year":"2020","journal-title":"Glob Med Genet"},{"key":"10.1016\/j.biomaterials.2025.123314_bib11","doi-asserted-by":"crossref","DOI":"10.12659\/MSM.944204","article-title":"Editorial: first regulatory approvals for CRISPR-Cas9 therapeutic gene editing for sickle cell disease and transfusion-dependent \u03b2-thalassemia","volume":"30","author":"Parums","year":"2024","journal-title":"Med. Sci. Monit."},{"issue":"18","key":"10.1016\/j.biomaterials.2025.123314_bib12","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJMoa2309676","article-title":"Exagamglogene autotemcel for severe sickle cell disease","volume":"390","author":"Frangoul","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.biomaterials.2025.123314_bib13","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa2309673","article-title":"Exagamglogene autotemcel for transfusion-dependent \u03b2-thalassemia","volume":"390","author":"Locatelli","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.biomaterials.2025.123314_bib14","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41431-019-0508-0","article-title":"Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database","volume":"28","author":"Nguengang Wakap","year":"2020","journal-title":"European journal of human genetics"},{"key":"10.1016\/j.biomaterials.2025.123314_bib15","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/s41578-019-0145-9","article-title":"Engineered materials for in vivo delivery of genome-editing machinery","volume":"4","author":"Tong","year":"2019","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.biomaterials.2025.123314_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.121204","article-title":"Clinical trials and promising preclinical applications of CRISPR\/Cas gene editing","volume":"312","author":"\u00c7er\u00e7i","year":"2023","journal-title":"Life Sci."},{"issue":"15","key":"10.1016\/j.biomaterials.2025.123314_bib17","doi-asserted-by":"crossref","first-page":"9874","DOI":"10.1021\/acs.chemrev.6b00799","article-title":"CRISPR\/Cas9-Based genome editing for disease modeling and therapy: challenges and opportunities for nonviral delivery","volume":"117","author":"Wang","year":"2017","journal-title":"Chem Rev"},{"issue":"40","key":"10.1016\/j.biomaterials.2025.123314_bib18","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abo0522","article-title":"In vivo correction of cystic fibrosis mediated by PNA nanoparticles","volume":"8","author":"Piotrowski-Daspit","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.biomaterials.2025.123314_bib19","first-page":"1","article-title":"A roadmap for affordable genetic medicines","author":"Kliegman","year":"2024","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.biomaterials.2025.123314_bib20","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/d41587-023-00016-6","article-title":"The world's first CRISPR therapy is approved: who will receive it?","volume":"42","author":"Sheridan","year":"2024","journal-title":"Nat. Biotechnol."},{"issue":"12","key":"10.1016\/j.biomaterials.2025.123314_bib21","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aar3952","article-title":"In vivo genome editing improves motor function and extends survival in a mouse model of ALS","volume":"3","author":"Gaj","year":"2017","journal-title":"Sci. Adv."},{"issue":"1","key":"10.1016\/j.biomaterials.2025.123314_bib22","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1146\/annurev-biophys-062215-010822","article-title":"CRISPR\u2013Cas9 structures and mechanisms","volume":"46","author":"Jiang","year":"2017","journal-title":"Annu. Rev. Biophys."},{"issue":"2","key":"10.1016\/j.biomaterials.2025.123314_bib23","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s00239-004-0046-3","article-title":"Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements","volume":"60","author":"Mojica","year":"2005","journal-title":"J. Mol. Evol."},{"issue":"1","key":"10.1016\/j.biomaterials.2025.123314_bib24","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.bj.2019.10.005","article-title":"CRISPR-Cas12a: functional overview and applications","volume":"43","author":"Paul","year":"2020","journal-title":"Biomed. J."},{"issue":"11","key":"10.1016\/j.biomaterials.2025.123314_bib25","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/s41580-019-0152-0","article-title":"DNA double-strand break repair-pathway choice in somatic mammalian cells","volume":"20","author":"Scully","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"5","key":"10.1016\/j.biomaterials.2025.123314_bib26","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/nbt.3190","article-title":"Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining","volume":"33","author":"Maruyama","year":"2015","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"10.1016\/j.biomaterials.2025.123314_bib27","article-title":"Efficient in vivo editing of OTC-deficient patient-derived primary human hepatocytes","volume":"2","author":"Ginn","year":"2020","journal-title":"JHEP Rep"},{"issue":"2","key":"10.1016\/j.biomaterials.2025.123314_bib28","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1093\/nar\/gkaa1251","article-title":"Dynamics and competition of CRISPR-Cas9 ribonucleoproteins and AAV donor-mediated NHEJ, MMEJ and HDR editing","volume":"49","author":"Fu","year":"2021","journal-title":"Nucleic Acids Res."},{"issue":"12","key":"10.1016\/j.biomaterials.2025.123314_bib29","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1002\/humu.21114","article-title":"Mutational spectrum of DMD mutations in dystrophinopathy patients: application of modern diagnostic techniques to a large cohort","volume":"30","author":"Flanigan","year":"2009","journal-title":"Hum. Mutat."},{"issue":"22","key":"10.1016\/j.biomaterials.2025.123314_bib30","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2004840117","article-title":"Toward the correction of muscular dystrophy by gene editing","volume":"118","author":"Olson","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"7631","key":"10.1016\/j.biomaterials.2025.123314_bib31","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/nature20565","article-title":"In vivo genome editing via CRISPR\/Cas9 mediated homology-independent targeted integration","volume":"540","author":"Suzuki","year":"2016","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.biomaterials.2025.123314_bib32","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/s41587-020-0561-9","article-title":"Genome editing with CRISPR\u2013Cas nucleases, base editors, transposases and prime","volume":"38","author":"Anzalone","year":"2020","journal-title":"Nat. Biotechnol."},{"issue":"7603","key":"10.1016\/j.biomaterials.2025.123314_bib33","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nature17946","article-title":"Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage","volume":"533","author":"Komor","year":"2016","journal-title":"Nature"},{"issue":"6305","key":"10.1016\/j.biomaterials.2025.123314_bib34","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaf8729","article-title":"Targeted nucleotide editing using hybrid prokaryotic and vertebrate adaptive immune systems","volume":"353","author":"Nishida","year":"2016","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.biomaterials.2025.123314_bib35","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/s41576-018-0059-1","article-title":"Base editing: precision chemistry on the genome and transcriptome of living cells","volume":"19","author":"Rees","year":"2018","journal-title":"Nat. Rev. Genet."},{"issue":"11","key":"10.1016\/j.biomaterials.2025.123314_bib36","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1038\/s41587-021-00938-z","article-title":"Efficient C\u2217G-to-G\u2217C base editors developed using CRISPRi screens, target-library analysis, and machine learning","volume":"39","author":"Koblan","year":"2021","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"10.1016\/j.biomaterials.2025.123314_bib37","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41587-020-0609-x","article-title":"CRISPR C-to-G base editors for inducing targeted DNA transversions in human cells","volume":"39","author":"Kurt","year":"2021","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"10.1016\/j.biomaterials.2025.123314_bib38","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41587-020-0592-2","article-title":"Glycosylase base editors enable C-to-A and C-to-G base changes","volume":"39","author":"Zhao","year":"2021","journal-title":"Nat. Biotechnol."},{"issue":"7785","key":"10.1016\/j.biomaterials.2025.123314_bib39","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-replace genome editing without double-strand breaks or donor DNA","volume":"576","author":"Anzalone","year":"2019","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.biomaterials.2025.123314_bib40","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41587-021-01133-w","article-title":"Programmable deletion, replacement, integration and inversion of large DNA sequences with twin prime editing","volume":"40","author":"Anzalone","year":"2022","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"10.1016\/j.biomaterials.2025.123314_bib41","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41551-024-01227-1","article-title":"Efficient site-specific integration of large genes in mammalian cells via continuously evolved recombinases and prime editing","volume":"9","author":"Pandey","year":"2025","journal-title":"Nat. Biomed. Eng."},{"issue":"8","key":"10.1016\/j.biomaterials.2025.123314_bib42","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/s41587-024-02320-1","article-title":"Epigenome editing technologies for discovery and medicine","volume":"42","author":"McCutcheon","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.biomaterials.2025.123314_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104682","article-title":"AAV-CRISPR-Cas13 eliminates human enterovirus and prevents death of infected mice","volume":"93","author":"Keng","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.biomaterials.2025.123314_bib44","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1126\/science.aaq0180","article-title":"RNA editing with CRISPR-Cas13","volume":"358","author":"Cox","year":"2017","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.biomaterials.2025.123314_bib45","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24010787","article-title":"Nanoparticles in clinical trials: analysis of clinical trials, FDA approvals and use for COVID-19 vaccines","volume":"24","author":"Namiot","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.biomaterials.2025.123314_bib46","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"issue":"6","key":"10.1016\/j.biomaterials.2025.123314_bib47","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.biomaterials.2025.123314_bib48","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41578-022-00529-7","article-title":"Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs","volume":"8","author":"Dilliard","year":"2023","journal-title":"Nat. Rev. Mater."},{"issue":"12","key":"10.1016\/j.biomaterials.2025.123314_bib49","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/s41565-019-0591-y","article-title":"The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs","volume":"14","author":"Akinc","year":"2019","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.biomaterials.2025.123314_bib50","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jconrel.2016.01.020","article-title":"Nanoparticle\u2013liver interactions: cellular uptake and hepatobiliary elimination","volume":"240","author":"Zhang","year":"2016","journal-title":"J. Contr. Release"},{"issue":"7","key":"10.1016\/j.biomaterials.2025.123314_bib51","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nbt.2612","article-title":"Image-based analysis of lipid nanoparticle\u2013mediated siRNA delivery, intracellular trafficking and endosomal escape","volume":"31","author":"Gilleron","year":"2013","journal-title":"Nat. Biotechnol."},{"issue":"6656","key":"10.1016\/j.biomaterials.2025.123314_bib52","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1126\/science.ade6967","article-title":"In vivo hematopoietic stem cell modification by mRNA delivery","volume":"381","author":"Breda","year":"2023","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.biomaterials.2025.123314_bib53","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/s41565-023-01563-4","article-title":"Strategies for non-viral vectors targeting organs beyond the liver","volume":"19","author":"Kim","year":"2024","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.biomaterials.2025.123314_bib54","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.jconrel.2022.12.008","article-title":"Engineering poly- and micelleplexes for nucleic acid delivery \u2013 a reflection on their endosomal escape","volume":"353","author":"Winkeljann","year":"2023","journal-title":"J. Contr. Release"},{"issue":"16","key":"10.1016\/j.biomaterials.2025.123314_bib55","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abm8011","article-title":"Blood-brain barrier-penetrating single CRISPR-Cas9 nanocapsules for effective and safe glioblastoma gene therapy","volume":"8","author":"Zou","year":"2022","journal-title":"Sci. Adv."},{"issue":"3","key":"10.1016\/j.biomaterials.2025.123314_bib56","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1021\/acs.nanolett.2c02306","article-title":"Phenylboronic acid-functionalized polyplexes tailored to oral CRISPR delivery","volume":"23","author":"Yoshinaga","year":"2023","journal-title":"Nano Lett."},{"issue":"1","key":"10.1016\/j.biomaterials.2025.123314_bib57","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1146\/annurev-med-042420-112725","article-title":"mRNA vaccines in the COVID-19 pandemic and beyond","volume":"73","author":"Hogan","year":"2022","journal-title":"Annu. Rev. Med."},{"issue":"15","key":"10.1016\/j.biomaterials.2025.123314_bib58","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.216259","article-title":"Viral escape from endosomes and host detection at a glance","volume":"131","author":"Staring","year":"2018","journal-title":"J. Cell Sci."},{"issue":"1","key":"10.1016\/j.biomaterials.2025.123314_bib59","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","article-title":"Viral vector platforms within the gene therapy landscape","volume":"6","author":"Bulcha","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.biomaterials.2025.123314_bib60","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12951-021-00806-7","article-title":"Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers","volume":"19","author":"Nooraei","year":"2021","journal-title":"J Nanobiotechnology"},{"issue":"17","key":"10.1016\/j.biomaterials.2025.123314_bib61","doi-asserted-by":"crossref","DOI":"10.1111\/jcmm.70056","article-title":"Gene and cell therapy of human genetic diseases: recent advances and future directions","volume":"28","author":"Cetin","year":"2024","journal-title":"J. Cell Mol. Med."},{"issue":"12","key":"10.1016\/j.biomaterials.2025.123314_bib62","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.1016\/j.ymthe.2022.10.010","article-title":"First-in-human in vivo genome editing via AAV-zinc-finger nucleases for mucopolysaccharidosis I\/II and hemophilia B","volume":"30","author":"Harmatz","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biomaterials.2025.123314_bib63","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1056\/NEJMoa2309915","article-title":"Gene editing for CEP290-associated retinal degeneration","volume":"390","author":"Pierce","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biomaterials.2025.123314_bib64","series-title":"Approved Cellular and Gene Therapy Products","year":"2024"},{"key":"10.1016\/j.biomaterials.2025.123314_bib65","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2023.1143157","article-title":"Off-target effects in CRISPR\/Cas9 gene editing","volume":"11","author":"Guo","year":"2023","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"1","key":"10.1016\/j.biomaterials.2025.123314_bib66","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.1038\/s41467-022-30480-8","article-title":"Cas9-induced large deletions and small indels are controlled in a convergent fashion","volume":"13","author":"Kosicki","year":"2022","journal-title":"Nat. Commun."},{"issue":"17","key":"10.1016\/j.biomaterials.2025.123314_bib67","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21176240","article-title":"CRISPR-Cas9 DNA base-editing and prime-editing","volume":"21","author":"Kantor","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.biomaterials.2025.123314_bib68","doi-asserted-by":"crossref","first-page":"4923","DOI":"10.1038\/s41467-023-40655-6","article-title":"AAV-mediated base-editing therapy ameliorates the disease phenotypes in a mouse model of retinitis pigmentosa","volume":"14","author":"Wu","year":"2023","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.biomaterials.2025.123314_bib69","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.celrep.2014.02.040","article-title":"Quantifying genome-editing outcomes at endogenous loci with SMRT sequencing","volume":"7","author":"Hendel","year":"2014","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.biomaterials.2025.123314_bib70","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-98965-y","article-title":"Optimized design parameters for CRISPR Cas9 and Cas12a homology-directed repair","volume":"11","author":"Schubert","year":"2021","journal-title":"Sci. Rep."},{"issue":"11","key":"10.1016\/j.biomaterials.2025.123314_bib71","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1038\/s41596-022-00724-4","article-title":"Designing and executing prime editing experiments in mammalian cells","volume":"17","author":"Doman","year":"2022","journal-title":"Nat. Protoc."},{"issue":"7","key":"10.1016\/j.biomaterials.2025.123314_bib72","article-title":"Safe and effective liver-directed AAV-mediated homology-independent targeted integration in mouse models of inherited diseases","volume":"5","author":"Esposito","year":"2024","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.biomaterials.2025.123314_bib73","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.662110","article-title":"On the corner of models and cure: gene editing in cystic fibrosis","volume":"12","author":"Ensinck","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"s2","key":"10.1016\/j.biomaterials.2025.123314_bib74","doi-asserted-by":"crossref","first-page":"S303","DOI":"10.3233\/JND-210678","article-title":"Gene therapy for Duchenne muscular dystrophy","volume":"8","author":"Elangkovan","year":"2021","journal-title":"J. Neuromuscul. Dis."},{"issue":"12","key":"10.1016\/j.biomaterials.2025.123314_bib75","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/s41434-021-00243-z","article-title":"Intracellular trafficking of adeno-associated virus (AAV) vectors: challenges and future directions","volume":"28","author":"Riyad","year":"2021","journal-title":"Gene Ther."},{"issue":"3","key":"10.1016\/j.biomaterials.2025.123314_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101295","article-title":"A self-complementary AAV proviral plasmid that reduces cross-packaging and ITR promoter activity in AAV vector preparations","volume":"32","author":"Taylor","year":"2024","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"2","key":"10.1016\/j.biomaterials.2025.123314_bib77","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.molmed.2020.09.010","article-title":"Journey to the center of the cell: tracing the path of AAV transduction","volume":"27","author":"Dhungel","year":"2021","journal-title":"Trends Mol. Med."},{"issue":"5","key":"10.1016\/j.biomaterials.2025.123314_bib78","doi-asserted-by":"crossref","DOI":"10.3390\/cells12050785","article-title":"Various AAV serotypes and their applications in gene therapy: an overview","volume":"12","author":"Issa","year":"2023","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.biomaterials.2025.123314_bib79","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.ymthe.2025.01.041","article-title":"A comprehensive atlas of AAV tropism in the mouse","volume":"33","author":"Walkey","year":"2025","journal-title":"Mol. Ther."},{"issue":"3","key":"10.1016\/j.biomaterials.2025.123314_bib80","doi-asserted-by":"crossref","first-page":"442","DOI":"10.3390\/v16030442","article-title":"Natural adeno-associated virus serotypes and engineered adeno-associated virus capsid variants: tropism differences and mechanistic insights","volume":"16","author":"Lopez-Gordo","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.biomaterials.2025.123314_bib81","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.omtm.2019.01.008","article-title":"Capsid modifications for targeting and improving the efficacy of AAV vectors","volume":"12","author":"Buning","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"7","key":"10.1016\/j.biomaterials.2025.123314_bib82","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens11070756","article-title":"Fantastic AAV gene therapy vectors and how to find them-random diversification, rational design and machine learning","volume":"11","author":"Becker","year":"2022","journal-title":"Pathogens"},{"issue":"1","key":"10.1016\/j.biomaterials.2025.123314_bib83","doi-asserted-by":"crossref","first-page":"6602","DOI":"10.1038\/s41467-024-50555-y","article-title":"Systematic multi-trait AAV capsid engineering for efficient gene delivery","volume":"15","author":"Eid","year":"2024","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.biomaterials.2025.123314_bib84","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.molmed.2022.01.003","article-title":"AAV capsid design: a Goldilocks challenge","volume":"28","author":"Zolotukhin","year":"2022","journal-title":"Trends Mol. Med."},{"issue":"29","key":"10.1016\/j.biomaterials.2025.123314_bib85","doi-asserted-by":"crossref","first-page":"13820","DOI":"10.1039\/D4NR01300J","article-title":"Chemical approaches to probe and engineer AAV vectors","volume":"16","author":"Pham","year":"2024","journal-title":"Nanoscale"},{"key":"10.1016\/j.biomaterials.2025.123314_bib86","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1001263","article-title":"rAAV immunogenicity, toxicity, and durability in 255 clinical trials: a meta-analysis","volume":"13","author":"Shen","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.biomaterials.2025.123314_bib87","doi-asserted-by":"crossref","first-page":"5432","DOI":"10.1038\/s41467-020-19230-w","article-title":"Identification of a myotropic AAV by massively parallel in vivo evaluation of barcoded capsid variants","volume":"11","author":"Weinmann","year":"2020","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.biomaterials.2025.123314_bib88","doi-asserted-by":"crossref","first-page":"6116","DOI":"10.1038\/s41467-023-41769-7","article-title":"Fast, multiplexable and efficient somatic gene deletions in adult mouse skeletal muscle fibers using AAV-CRISPR\/Cas9","volume":"14","author":"Thurkauf","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biomaterials.2025.123314_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2023.122399","article-title":"AAV vectors displaying bispecific DARPins enable dual-control targeted gene delivery","volume":"303","author":"Theuerkauf","year":"2023","journal-title":"Biomaterials"},{"issue":"2","key":"10.1016\/j.biomaterials.2025.123314_bib90","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.cell.2022.12.022","article-title":"An evolved AAV variant enables efficient genetic engineering of murine T cells","volume":"186","author":"Nyberg","year":"2023","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.biomaterials.2025.123314_bib91","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/s41434-022-00375-w","article-title":"In vivo genome editing using novel AAV-PHP variants rescues motor function deficits and extends survival in a SOD1-ALS mouse model","volume":"30","author":"Chen","year":"2023","journal-title":"Gene Ther."},{"issue":"1","key":"10.1016\/j.biomaterials.2025.123314_bib92","doi-asserted-by":"crossref","first-page":"7401","DOI":"10.1038\/s41598-017-07642-6","article-title":"ssAAVs containing cassettes encoding SaCas9 and guides targeting hepatitis B virus inactivate replication of the virus in cultured cells","volume":"7","author":"Scott","year":"2017","journal-title":"Sci. Rep."},{"issue":"6271","key":"10.1016\/j.biomaterials.2025.123314_bib93","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1126\/science.aad5177","article-title":"In vivo gene editing in dystrophic mouse muscle and muscle stem cells","volume":"351","author":"Tabebordbar","year":"2016","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.biomaterials.2025.123314_bib94","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.ymthe.2020.04.017","article-title":"AAV-CRISPR gene editing is negated by pre-existing immunity to Cas9","volume":"28","author":"Li","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biomaterials.2025.123314_bib95","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.omtm.2018.11.009","article-title":"A self-deleting AAV-CRISPR system for in vivo genome editing","volume":"12","author":"Li","year":"2019","journal-title":"Molecular Therapy-Methods & Clinical Development"},{"key":"10.1016\/j.biomaterials.2025.123314_bib96","author":"BioTherapeutics"},{"issue":"755","key":"10.1016\/j.biomaterials.2025.123314_bib97","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adn0689","article-title":"Targeted genome editing restores auditory function in adult mice with progressive hearing loss caused by a human microRNA mutation","volume":"16","author":"Zhu","year":"2024","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.biomaterials.2025.123314_bib98","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ymthe.2021.10.023","article-title":"AAV5 delivery of CRISPR-Cas9 supports effective genome editing in mouse lung airway","volume":"30","author":"Liang","year":"2022","journal-title":"Mol. Ther."},{"issue":"6410","key":"10.1016\/j.biomaterials.2025.123314_bib99","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1126\/science.aau1549","article-title":"Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy","volume":"362","author":"Amoasii","year":"2018","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.biomaterials.2025.123314_bib100","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/nbt.3469","article-title":"A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice","volume":"34","author":"Yang","year":"2016","journal-title":"Nat. Biotechnol."},{"issue":"4","key":"10.1016\/j.biomaterials.2025.123314_bib101","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1006\/mthe.2001.0456","article-title":"Expanding AAV packaging capacity with trans-splicing or overlapping vectors: a quantitative comparison","volume":"4","author":"Duan","year":"2001","journal-title":"Mol. Ther."},{"issue":"3","key":"10.1016\/j.biomaterials.2025.123314_bib102","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1089\/hum.2008.173","article-title":"Functional cystic fibrosis transmembrane conductance regulator expression in cystic fibrosis airway epithelial cells by AAV6. 2-mediated segmental trans-splicing","volume":"20","author":"Song","year":"2009","journal-title":"Hum. Gene Ther."},{"issue":"1","key":"10.1016\/j.biomaterials.2025.123314_bib103","doi-asserted-by":"crossref","first-page":"6578","DOI":"10.1038\/s41467-023-42386-0","article-title":"mRNA trans-splicing dual AAV vectors for (epi)genome editing and gene therapy","volume":"14","author":"Riedmayr","year":"2023","journal-title":"Nat. Commun."},{"issue":"492","key":"10.1016\/j.biomaterials.2025.123314_bib104","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav4523","article-title":"Intein-mediated protein trans-splicing expands adeno-associated virus transfer capacity in the retina","volume":"11","author":"Tornabene","year":"2019","journal-title":"Sci. Transl. Med."},{"issue":"6","key":"10.1016\/j.biomaterials.2025.123314_bib105","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/nbt.4148","article-title":"Adenine base editing in mouse embryos and an adult mouse model of Duchenne muscular dystrophy","volume":"36","author":"Ryu","year":"2018","journal-title":"Nat. Biotechnol."},{"issue":"6723","key":"10.1016\/j.biomaterials.2025.123314_bib106","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1126\/science.adp8179","article-title":"Ribozyme-activated mRNA trans-ligation enables large gene delivery to treat muscular dystrophies","volume":"386","author":"Lindley","year":"2024","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.biomaterials.2025.123314_bib107","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41551-019-0501-5","article-title":"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses","volume":"4","author":"Levy","year":"2020","journal-title":"Nat. Biomed. Eng."},{"issue":"21","key":"10.1016\/j.biomaterials.2025.123314_bib108","doi-asserted-by":"crossref","first-page":"14490","DOI":"10.1074\/jbc.R114.548255","article-title":"Enigmatic distribution, evolution, and function of inteins","volume":"289","author":"Novikova","year":"2014","journal-title":"J. Biol. Chem."},{"issue":"13","key":"10.1016\/j.biomaterials.2025.123314_bib109","doi-asserted-by":"crossref","first-page":"6450","DOI":"10.1093\/nar\/gkv601","article-title":"Development of an intein-mediated split\u2013Cas9 system for gene therapy","volume":"43","author":"Truong","year":"2015","journal-title":"Nucleic acids research"},{"issue":"13\u201314","key":"10.1016\/j.biomaterials.2025.123314_bib110","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1089\/hum.2023.055","article-title":"Screening an effective dual-adeno-associated virus split-cytosine base editor system for C-to-T conversion in vivo","volume":"34","author":"Liu","year":"2023","journal-title":"Hum. Gene Ther."},{"issue":"2","key":"10.1016\/j.biomaterials.2025.123314_bib111","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41551-023-01132-z","article-title":"Optimization of base editors for the functional correction of SMN2 as a treatment for spinal muscular atrophy","volume":"8","author":"Alves","year":"2024","journal-title":"Nat. Biomed. Eng."},{"issue":"1","key":"10.1016\/j.biomaterials.2025.123314_bib112","doi-asserted-by":"crossref","first-page":"5927","DOI":"10.1038\/s41467-024-50340-x","article-title":"Adenine base editing-mediated exon skipping restores dystrophin in humanized Duchenne mouse model","volume":"15","author":"Lin","year":"2024","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.biomaterials.2025.123314_bib113","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41392-022-01234-1","article-title":"Dual-AAV split prime editor corrects the mutation and phenotype in mice with inherited retinal degeneration","volume":"8","author":"She","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"5","key":"10.1016\/j.biomaterials.2025.123314_bib114","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1039\/C4MB00021H","article-title":"Structure-based engineering and comparison of novel split inteins for protein ligation","volume":"10","author":"Aranko","year":"2014","journal-title":"Mol. Biosyst."},{"issue":"1","key":"10.1016\/j.biomaterials.2025.123314_bib115","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13059-024-03257-z","article-title":"Enhancing prime editor flexibility with coiled-coil heterodimers","volume":"25","author":"Mu","year":"2024","journal-title":"Genome Biol."},{"issue":"11","key":"10.1016\/j.biomaterials.2025.123314_bib116","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1038\/s41551-022-00911-4","article-title":"Efficient in vivo base editing via single adeno-associated viruses with size-optimized genomes encoding compact adenine base editors","volume":"6","author":"Davis","year":"2022","journal-title":"Nat. Biomed. Eng."},{"issue":"24","key":"10.1016\/j.biomaterials.2025.123314_bib117","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1093\/hmg\/ddae144","article-title":"Delivering large genes using adeno-associated virus and the CRE-lox DNA recombination system","volume":"33","author":"Datta","year":"2024","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.biomaterials.2025.123314_bib118","article-title":"Gene therapy advances: a meta-analysis of AAV usage in clinical settings","volume":"8","author":"Au","year":"2021","journal-title":"Front. Med."},{"issue":"3\u20134","key":"10.1016\/j.biomaterials.2025.123314_bib119","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41434-019-0105-4","article-title":"Transduction optimization of AAV vectors for human gene therapy of glaucoma and their reversed cell entry characteristics","volume":"27","author":"Rodriguez-Estevez","year":"2020","journal-title":"Gene Ther."},{"issue":"8","key":"10.1016\/j.biomaterials.2025.123314_bib120","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aay6812","article-title":"Enhanced CRISPR-Cas9 correction of Duchenne muscular dystrophy in mice by a self-complementary AAV delivery system","volume":"6","author":"Zhang","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.biomaterials.2025.123314_bib121","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.omtm.2023.05.013","article-title":"Strong ubiquitous micro-promoters for recombinant adeno-associated viral vectors","volume":"29","author":"Chai","year":"2023","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"11","key":"10.1016\/j.biomaterials.2025.123314_bib122","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1002\/biot.201400046","article-title":"CRISPR\/Cas9\u2010mediated genome engineering: an adeno\u2010associated viral (AAV) vector toolbox","volume":"9","author":"Sen\u00eds","year":"2014","journal-title":"Biotechnol. J."},{"issue":"9","key":"10.1016\/j.biomaterials.2025.123314_bib123","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41434-020-0142-z","article-title":"\u2018Mini\u2019 U6 Pol III promoter exhibits nucleosome redundancy and supports multiplexed coupling of CRISPR\/Cas9 effects","volume":"27","author":"Preece","year":"2020","journal-title":"Gene Ther."},{"key":"10.1016\/j.biomaterials.2025.123314_bib124","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.omtn.2018.05.001","article-title":"RNA polymerase II activity of type 3 Pol III promoters","volume":"12","author":"Gao","year":"2018","journal-title":"Molecular Therapy-Nucleic Acids"},{"key":"10.1016\/j.biomaterials.2025.123314_bib125","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.omtn.2018.10.016","article-title":"A single H1 promoter can drive both guide RNA and endonuclease expression in the CRISPR-Cas9 system","volume":"14","author":"Gao","year":"2019","journal-title":"Molecular Therapy-Nucleic Acids"},{"key":"10.1016\/j.biomaterials.2025.123314_bib126","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.csbj.2019.11.006","article-title":"ComputationalapproachesforeffectiveCRISPRguideRNAdesignand evaluation","volume":"18","author":"Liu","year":"2020","journal-title":"Comput. Struct. Biotechnol. J."},{"issue":"1","key":"10.1016\/j.biomaterials.2025.123314_bib127","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41596-020-00431-y","article-title":"Tools for experimental and computational analyses of off-target editing by programmable nucleases","volume":"16","author":"Bao","year":"2021","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.biomaterials.2025.123314_bib128","series-title":"PnB Designer: a web application to design prime and base editor guide RNAs for animals and plants, BMC Bioinf","first-page":"22","author":"Siegner","year":"2021"},{"issue":"24","key":"10.1016\/j.biomaterials.2025.123314_bib129","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1093\/bioinformatics\/btv537","article-title":"Cas-Designer: a web-based tool for choice of CRISPR-Cas9 target sites","volume":"31","author":"Park","year":"2015","journal-title":"Bioinformatics"},{"key":"10.1016\/j.biomaterials.2025.123314_bib130","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1038\/s42256-023-00739-w","article-title":"Design of prime-editing guide RNAs with deep transfer learning","volume":"5","author":"Liu","year":"2023","journal-title":"Nat. Mach. Intell."},{"key":"10.1016\/j.biomaterials.2025.123314_bib131","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkab319","article-title":"PE-Designer and PE-Analyzer: web-based design and analysis tools for CRISPR prime editing","volume":"49","author":"Hwang","year":"2021","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.biomaterials.2025.123314_bib132","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkab427","article-title":"pegIT - a web-based design tool for prime editing","volume":"49","author":"Anderson","year":"2021","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.biomaterials.2025.123314_bib133","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41587-021-01039-7","article-title":"Engineered pegRNAs improve prime editing efficiency","volume":"40","author":"Nelson","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.biomaterials.2025.123314_bib134","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkad456","article-title":"Reducing the inherent auto-inhibitory interaction within the pegRNA enhances prime editing efficiency","volume":"51","author":"Ponnienselvan","year":"2023","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.biomaterials.2025.123314_bib135","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.90948.2","article-title":"Enhancing CRISPR prime editing by reducing misfolded pegRNA interactions","volume":"12","author":"Zhang","year":"2024","journal-title":"Elife"},{"key":"10.1016\/j.biomaterials.2025.123314_bib136","doi-asserted-by":"crossref","DOI":"10.1016\/j.cobme.2023.100478","article-title":"Detection and quantification of unintended large on-target gene modifications due to CRISPR\/Cas9 editing","volume":"28","author":"Park","year":"2023","journal-title":"Current Opinion in Biomedical Engineering"},{"issue":"42","key":"10.1016\/j.biomaterials.2025.123314_bib137","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abo7676","article-title":"Comprehensive analysis and accurate quantification of unintended large gene modifications induced by CRISPR-Cas9 gene editing","volume":"8","author":"Park","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.biomaterials.2025.123314_bib138","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/nature14299","article-title":"Vivo genome editing using Staphylococcus aureus Cas9","volume":"520","author":"Ran","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.biomaterials.2025.123314_bib139","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41551-019-0501-5","article-title":"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses","volume":"4","author":"Levy","year":"2020","journal-title":"Nat. Biomed. Eng."},{"issue":"1","key":"10.1016\/j.biomaterials.2025.123314_bib140","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1038\/s41467-021-26518-y","article-title":"Self-inactivating, all-in-one AAV vectors for precision Cas9 genome editing via homology-directed repair in vivo","volume":"12","author":"Ibraheim","year":"2021","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.biomaterials.2025.123314_bib141","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3002619","article-title":"Engineering of a compact, high-fidelity EbCas12a variant that can be packaged with its crRNA into an all-in-one AAV vector delivery system","volume":"22","author":"Wang","year":"2024","journal-title":"PLoS Biol."},{"issue":"3","key":"10.1016\/j.biomaterials.2025.123314_bib142","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/s41589-023-01481-5","article-title":"Phage-assisted evolution of compact Cas9 variants targeting a simple NNG PAM","volume":"20","author":"Qi","year":"2024","journal-title":"Nat. Chem. Biol."},{"issue":"1","key":"10.1016\/j.biomaterials.2025.123314_bib143","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41587-022-01410-2","article-title":"High-throughput continuous evolution of compact Cas9 variants targeting single-nucleotide-pyrimidine PAMs","volume":"41","author":"Huang","year":"2023","journal-title":"Nat. Biotechnol."},{"issue":"7","key":"10.1016\/j.biomaterials.2025.123314_bib144","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3000747","article-title":"High-fidelity SaCas9 identified by directional screening in human cells","volume":"18","author":"Xie","year":"2020","journal-title":"PLoS Biol."},{"issue":"8","key":"10.1016\/j.biomaterials.2025.123314_bib145","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1038\/s41591-018-0137-0","article-title":"A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells","volume":"24","author":"Vakulskas","year":"2018","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.biomaterials.2025.123314_bib146","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1038\/s41589-023-01279-5","article-title":"Sniper2L is a high-fidelity Cas9 variant with high activity","volume":"19","author":"Kim","year":"2023","journal-title":"Nat. Chem. Biol."},{"issue":"1","key":"10.1016\/j.biomaterials.2025.123314_bib147","doi-asserted-by":"crossref","first-page":"6082","DOI":"10.1038\/s41467-020-19842-2","article-title":"MiCas9 increases large size gene knock-in rates and reduces undesirable on-target and off-target indel edits","volume":"11","author":"Ma","year":"2020","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.biomaterials.2025.123314_bib148","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3000686","article-title":"A compact Cas9 ortholog from Staphylococcus Auricularis (SauriCas9) expands the DNA targeting scope","volume":"18","author":"Hu","year":"2020","journal-title":"PLoS Biol."},{"issue":"7","key":"10.1016\/j.biomaterials.2025.123314_bib149","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.1093\/nar\/gkab148","article-title":"Discovery and engineering of small SlugCas9 with broad targeting range and high specificity and activity","volume":"49","author":"Hu","year":"2021","journal-title":"Nucleic Acids Res."},{"issue":"39","key":"10.1016\/j.biomaterials.2025.123314_bib150","doi-asserted-by":"crossref","first-page":"15644","DOI":"10.1073\/pnas.1313587110","article-title":"Efficient genome engineering in human pluripotent stem cells using Cas9 from Neisseria meningitidis","volume":"110","author":"Hou","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.biomaterials.2025.123314_bib151","article-title":"In vivo genome editing with a small Cas9 orthologue derived from Campylobacter jejuni","volume":"8","author":"Kim","year":"2017","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.biomaterials.2025.123314_bib152","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.cell.2015.09.038","article-title":"Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system","volume":"163","author":"Zetsche","year":"2015","journal-title":"cell"},{"issue":"7743","key":"10.1016\/j.biomaterials.2025.123314_bib153","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41586-019-0908-x","article-title":"CasX enzymes comprise a distinct family of RNA-guided genome editors","volume":"566","author":"Liu","year":"2019","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.biomaterials.2025.123314_bib154","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1038\/s41589-021-00868-6","article-title":"Programmed genome editing by a miniature CRISPR-Cas12f nuclease","volume":"17","author":"Wu","year":"2021","journal-title":"Nat. Chem. Biol."},{"issue":"1","key":"10.1016\/j.biomaterials.2025.123314_bib155","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41587-021-01009-z","article-title":"Efficient CRISPR editing with a hypercompact Cas12f1 and engineered guide RNAs delivered by adeno-associated virus","volume":"40","author":"Kim","year":"2022","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"10.1016\/j.biomaterials.2025.123314_bib156","doi-asserted-by":"crossref","first-page":"6191","DOI":"10.1038\/s41467-021-26469-4","article-title":"Miniature type V-F CRISPR-Cas nucleases enable targeted DNA modification in cells","volume":"12","author":"Bigelyte","year":"2021","journal-title":"Nat. Commun."},{"issue":"6501","key":"10.1016\/j.biomaterials.2025.123314_bib157","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1126\/science.abb1400","article-title":"CRISPR-Cas\u03a6 from huge phages is a hypercompact genome editor","volume":"369","author":"Pausch","year":"2020","journal-title":"Science"},{"issue":"7\u20138","key":"10.1016\/j.biomaterials.2025.123314_bib158","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/s41434-022-00319-4","article-title":"Two high-fidelity variants: efSaCas9 and SaCas9-HF, which one is better?","volume":"29","author":"Lv","year":"2022","journal-title":"Gene Ther."},{"issue":"7","key":"10.1016\/j.biomaterials.2025.123314_bib159","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/s41592-023-01875-2","article-title":"Massively parallel evaluation and computational prediction of the activities and specificities of 17 small Cas9s","volume":"20","author":"Seo","year":"2023","journal-title":"Nat. Methods"},{"issue":"2","key":"10.1016\/j.biomaterials.2025.123314_bib160","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s12276-023-00938-w","article-title":"Targeted dual base editing with Campylobacter jejuni Cas9 by single AAV-mediated delivery","volume":"55","author":"Kweon","year":"2023","journal-title":"Exp. Mol. Med."},{"issue":"3","key":"10.1016\/j.biomaterials.2025.123314_bib161","doi-asserted-by":"crossref","DOI":"10.1089\/genbio.2022.0015","article-title":"Adenine base editing in vivo with a single adeno-associated virus vector","volume":"1","author":"Zhang","year":"2022","journal-title":"GEN Biotechnology"},{"issue":"2","key":"10.1016\/j.biomaterials.2025.123314_bib162","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102201","article-title":"Engineering miniature CRISPR-Cas Un1Cas12f1 for efficient base editing","volume":"35","author":"Hu","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"2","key":"10.1016\/j.biomaterials.2025.123314_bib163","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1093\/nar\/gkad1125","article-title":"Self-delivering, chemically modified CRISPR RNAs for AAV co-delivery and genome editing in vivo","volume":"52","author":"Zhang","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.biomaterials.2025.123314_bib164","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.omtm.2018.02.003","article-title":"Influence of pre-existing anti-capsid neutralizing and binding antibodies on AAV vector transduction","volume":"9","author":"Fitzpatrick","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.biomaterials.2025.123314_bib165","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.975803","article-title":"Immunogenicity and toxicity of AAV gene therapy","volume":"13","author":"Ertl","year":"2022","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.biomaterials.2025.123314_bib166","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1016\/j.ymthe.2023.10.015","article-title":"Mini-review: lethal immunotoxicity in high-dose systemic AAV therapy","volume":"31","author":"Duan","year":"2023","journal-title":"Mol. Ther."},{"issue":"3","key":"10.1016\/j.biomaterials.2025.123314_bib167","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.ymthe.2020.01.001","article-title":"Immune responses to viral gene therapy vectors","volume":"28","author":"Shirley","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biomaterials.2025.123314_bib168","doi-asserted-by":"crossref","first-page":"670","DOI":"10.3389\/fimmu.2020.00670","article-title":"Human immune responses to adeno-associated virus (AAV) vectors","volume":"11","author":"Ronzitti","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biomaterials.2025.123314_bib169","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.omtm.2022.02.011","article-title":"Testing preexisting antibodies prior to AAV gene transfer therapy: rationale, lessons and future considerations","volume":"25","author":"Mendell","year":"2022","journal-title":"Molecular Therapy - Methods & Clinical Development"},{"issue":"1","key":"10.1016\/j.biomaterials.2025.123314_bib170","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3390\/v13010101","article-title":"Completion of the AAV structural atlas: serotype capsid structures reveals clade-specific features","volume":"13","author":"Mietzsch","year":"2021","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.biomaterials.2025.123314_bib171","doi-asserted-by":"crossref","first-page":"9322","DOI":"10.1038\/s41598-021-88614-9","article-title":"Engineered adeno-associated virus 3 vector with reduced reactivity to serum antibodies","volume":"11","author":"Ito","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biomaterials.2025.123314_bib172","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.omtm.2023.08.016","article-title":"Efficient gene transduction in pigs and macaques with the engineered AAV vector AAV.GT5 for hemophilia B gene therapy","volume":"30","author":"Kashiwakura","year":"2023","journal-title":"Molecular Therapy Methods & Clinical Development"},{"issue":"5","key":"10.1016\/j.biomaterials.2025.123314_bib173","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1161\/CIRCULATIONAHA.122.063759","article-title":"Extracellular vesicle\u2013encapsulated adeno-associated viruses for therapeutic gene delivery to the heart","volume":"148","author":"Li","year":"2023","journal-title":"Circulation"},{"issue":"26","key":"10.1016\/j.biomaterials.2025.123314_bib174","doi-asserted-by":"crossref","first-page":"7598","DOI":"10.1016\/j.biomaterials.2014.05.032","article-title":"Naturally enveloped AAV vectors for shielding neutralizing antibodies and robust gene delivery in vivo","volume":"35","author":"Gy\u00f6rgy","year":"2014","journal-title":"Biomaterials"},{"issue":"24","key":"10.1016\/j.biomaterials.2025.123314_bib175","first-page":"6459","article-title":"The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9\u2013dependent innate immune responses in the liver","volume":"117","author":"Martino","year":"2011","journal-title":"Blood, The Journal of the American Society of Hematology"},{"issue":"3","key":"10.1016\/j.biomaterials.2025.123314_bib176","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1159\/000369273","article-title":"Unique roles of TLR9-and MyD88-dependent and-independent pathways in adaptive immune responses to AAV-mediated gene transfer","volume":"7","author":"Rogers","year":"2015","journal-title":"J. Innate Immun."},{"issue":"580","key":"10.1016\/j.biomaterials.2025.123314_bib177","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd3438","article-title":"Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses","volume":"13","author":"Chan","year":"2021","journal-title":"Sci. Transl. Med."},{"issue":"9\u201310","key":"10.1016\/j.biomaterials.2025.123314_bib178","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1089\/hum.2023.056","article-title":"Immune responses to muscle-directed adeno-associated viral gene transfer in clinical studies","volume":"34","author":"Kumar","year":"2023","journal-title":"Hum. Gene Ther."},{"issue":"14","key":"10.1016\/j.biomaterials.2025.123314_bib179","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.1182\/bloodadvances.2021006419","article-title":"Fatal thrombotic microangiopathy case following adeno-associated viral SMN gene therapy","volume":"6","author":"Guillou","year":"2022","journal-title":"Blood Advances"},{"key":"10.1016\/j.biomaterials.2025.123314_bib180","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jpeds.2020.11.054","article-title":"Thrombotic microangiopathy following onasemnogene abeparvovec for spinal muscular atrophy: a case series","volume":"231","author":"Chand","year":"2021","journal-title":"J. Pediatr."},{"issue":"10","key":"10.1016\/j.biomaterials.2025.123314_bib181","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/s41417-021-00413-6","article-title":"Safety of Adeno-associated virus-based vector-mediated gene therapy\u2014impact of vector dose","volume":"29","author":"Maurya","year":"2022","journal-title":"Cancer Gene Ther."},{"issue":"1","key":"10.1016\/j.biomaterials.2025.123314_bib182","article-title":"Immunity to CRISPR Cas9 and Cas12a therapeutics","volume":"10","author":"Chew","year":"2018","journal-title":"Wiley Interdisciplinary Reviews: Systems Biology and Medicine"},{"issue":"2","key":"10.1016\/j.biomaterials.2025.123314_bib183","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/s41591-018-0204-6","article-title":"High prevalence of Streptococcus pyogenes Cas9-reactive T cells within the adult human population","volume":"25","author":"Wagner","year":"2019","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.biomaterials.2025.123314_bib184","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s41591-018-0326-x","article-title":"Identification of preexisting adaptive immunity to Cas9 proteins in humans","volume":"25","author":"Charlesworth","year":"2019","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.biomaterials.2025.123314_bib185","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1038\/s41467-019-09693-x","article-title":"Multifunctional CRISPR-Cas9 with engineered immunosilenced human T cell epitopes","volume":"10","author":"Ferdosi","year":"2019","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.biomaterials.2025.123314_bib186","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/nmeth.3993","article-title":"A multifunctional AAV-CRISPR-Cas9 and its host response","volume":"13","author":"Chew","year":"2016","journal-title":"Nat. Methods"},{"issue":"1","key":"10.1016\/j.biomaterials.2025.123314_bib187","doi-asserted-by":"crossref","first-page":"6769","DOI":"10.1038\/s41467-021-26830-7","article-title":"Cas9-specific immune responses compromise local and systemic AAV CRISPR therapy in multiple dystrophic canine models","volume":"12","author":"Hakim","year":"2021","journal-title":"Nat. Commun."},{"issue":"22","key":"10.1016\/j.biomaterials.2025.123314_bib188","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1161\/CIRCULATIONAHA.123.065438","article-title":"MicroRNA-122-Mediated liver detargeting enhances the tissue specificity of cardiac genome editing","volume":"149","author":"Yang","year":"2024","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.biomaterials.2025.123314_bib189","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ymthe.2019.01.015","article-title":"Protease-activatable adeno-associated virus vector for gene delivery to damaged heart tissue","volume":"27","author":"Guenther","year":"2019","journal-title":"Mol. Ther."},{"issue":"3","key":"10.1016\/j.biomaterials.2025.123314_bib190","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.ymthe.2020.12.028","article-title":"Increasing the specificity of AAV-based gene editing through self-targeting and short-promoter strategies","volume":"29","author":"Breton","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biomaterials.2025.123314_bib191","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.omtm.2021.02.005","article-title":"In vivo PCSK9 gene editing using an all-in-one self-cleavage AAV-CRISPR system","volume":"20","author":"Li","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1","key":"10.1016\/j.biomaterials.2025.123314_bib192","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1146\/annurev.genet.37.110801.143717","article-title":"Integration of adeno-associated virus (AAV) and recombinant AAV vectors","volume":"38","author":"McCarty","year":"2004","journal-title":"Annu. Rev. Genet."},{"issue":"1","key":"10.1016\/j.biomaterials.2025.123314_bib193","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41587-020-0741-7","article-title":"A long-term study of AAV gene therapy in dogs with hemophilia A identifies clonal expansions of transduced liver cells","volume":"39","author":"Nguyen","year":"2021","journal-title":"Nat. Biotechnol."},{"issue":"2","key":"10.1016\/j.biomaterials.2025.123314_bib194","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s41587-024-02171-w","article-title":"Genome engineering with Cas9 and AAV repair templates generates frequent concatemeric insertions of viral vectors","volume":"43","author":"Suchy","year":"2024","journal-title":"Nat. Biotechnol."},{"issue":"3","key":"10.1016\/j.biomaterials.2025.123314_bib195","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.ymthe.2023.01.004","article-title":"Targeted long-read sequencing captures CRISPR editing and AAV integration outcomes in brain","volume":"31","author":"Simpson","year":"2023","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.biomaterials.2025.123314_bib196","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1038\/s41467-019-12449-2","article-title":"High levels of AAV vector integration into CRISPR-induced DNA breaks","volume":"10","author":"Hanlon","year":"2019","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.biomaterials.2025.123314_bib197","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/ng1380","article-title":"Adeno-associated virus vectors integrate at chromosome breakage sites","volume":"36","author":"Miller","year":"2004","journal-title":"Nat. Genet."},{"issue":"7","key":"10.1016\/j.biomaterials.2025.123314_bib200","first-page":"6097","article-title":"Safety and expression following subretinal administration of AAV.ABCA4.intein vectors in the non-human primate retina","volume":"65","author":"Leroy","year":"2024","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"7","key":"10.1016\/j.biomaterials.2025.123314_bib201","first-page":"6089","article-title":"Preclinical safety and efficacy of intein-based dual-AAV gene therapy for Stargardt disease","volume":"65","author":"Favre","year":"2024","journal-title":"Investigative Ophthalmology & Visual Science"},{"key":"10.1016\/j.biomaterials.2025.123314_bib202","article-title":"A versatile toolkit for overcoming AAV immunity","volume":"13","author":"Li","year":"2022","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.biomaterials.2025.123314_bib203","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/s41551-023-01129-8","article-title":"Rational immunosilencing of a promiscuous T-cell epitope in the capsid of an adeno-associated virus","volume":"8","author":"Bing","year":"2024","journal-title":"Nat. Biomed. Eng."},{"issue":"1","key":"10.1016\/j.biomaterials.2025.123314_bib204","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/s41467-024-55522-1","article-title":"Rational engineering of minimally immunogenic nucleases for gene therapy","volume":"16","author":"Raghavan","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biomaterials.2025.123314_bib205","unstructured":"D. Maura, J. Yu, X.-Q. Ren, M. Child, R. Kaur, Z. Thorpe, J. Liu, N. Gebremedhin, D. Cox, W. Chen, B. Hoffman, T. Moyer, A. Sayed-Zahid, J. Yao, C. Chung, T. Carter, M. Nonnenmacher, Discovery of TRACER AAV Capsids Escaping Pre-existing Neutralizing Antibodies, ASGCT 27th Annual Meeting, Baltimore, MD, USA."},{"key":"10.1016\/j.biomaterials.2025.123314_bib206","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2023.102050","article-title":"In vivo genome editing using 244-cis LNPs and low-dose AAV achieves therapeutic threshold in hemophilia A mice","volume":"34","author":"Han","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.biomaterials.2025.123314_bib207","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.omtn.2023.03.008","article-title":"In vivo genome editing for hemophilia B therapy by the combination of rebalancing and therapeutic gene knockin using a viral and non-viral vector","volume":"32","author":"Lee","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"}],"container-title":["Biomaterials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961225002339?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961225002339?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T04:34:56Z","timestamp":1777782896000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0142961225002339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":205,"alternative-id":["S0142961225002339"],"URL":"https:\/\/doi.org\/10.1016\/j.biomaterials.2025.123314","relation":{},"ISSN":["0142-9612"],"issn-type":[{"value":"0142-9612","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Engineering adeno-associated viral vectors for CRISPR\/Cas based in vivo therapeutic genome editing","name":"articletitle","label":"Article Title"},{"value":"Biomaterials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biomaterials.2025.123314","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"123314"}}